| Needs review |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 3 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 4 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 5 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 6 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 7 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 8 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 9 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 10 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 11 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 12 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 13 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 14 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 15 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 16 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 17 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 18 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 19 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 20 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 21 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 22 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 23 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 24 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 25 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 26 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 27 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 28 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 29 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 30 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 31 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 32 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 33 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 34 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 35 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 36 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 37 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 38 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 39 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 40 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 41 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 42 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 43 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 44 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 45 |
| A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients |
| A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 1 |
| A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 1/Signature 1 |
| A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 1/Signature 2 |
| A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 2 |
| A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 2/Signature 1 |
| A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients/Experiment 2/Signature 2 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3 |
| Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon |
| Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 1 |
| Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 1/Signature 1 |
| Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 1/Signature 2 |
| Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 2 |
| Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon/Experiment 2/Signature 1 |
| Alteration of the gut microbiota profile in children with autism spectrum disorder in China |
| Alteration of the gut microbiota profile in children with autism spectrum disorder in China/Experiment 1 |
| Alteration of the gut microbiota profile in children with autism spectrum disorder in China/Experiment 1/Signature 1 |
| Alteration of the gut microbiota profile in children with autism spectrum disorder in China/Experiment 1/Signature 2 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 1 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 1/Signature 1 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 1/Signature 2 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 2 |
| Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet/Experiment 2/Signature 1 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 1 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 1/Signature 1 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 1/Signature 2 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 2 |
| Altered Gut Microbiota in Chinese Children With Autism Spectrum Disorders/Experiment 2/Signature 1 |
| Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome |
| Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 1 |
| Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 1/Signature 1 |
| Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 1/Signature 2 |
| Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 3 |
| Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 3/Signature 1 |
| Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome/Experiment 3/Signature 2 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1 |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 1 |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 2 |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 2/Signature 1 |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 3 |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 3/Signature 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 1/Signature 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 1/Signature 2 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 2 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 2/Signature 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 2/Signature 2 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 3 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 3/Signature 1 |
| Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly/Experiment 3/Signature 2 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 1 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 1/Signature 1 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 1/Signature 2 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 2 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 2/Signature 1 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 2/Signature 2 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 3 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 3/Signature 1 |
| Bacteriome analysis of Aggregatibacter actinomycetemcomitans-JP2 genotype-associated Grade C periodontitis in Moroccan adolescents/Experiment 3/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 3 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 4 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 5 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 6 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 7 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 8 |
| Body site-typical microbiome signatures for children/Experiment 2 |
| Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria/Experiment 2 |
| Changes in social environment impact primate gut microbiota composition |
| Changes in social environment impact primate gut microbiota composition/Experiment 1 |
| Changes in social environment impact primate gut microbiota composition/Experiment 1/Signature 1 |
| Changes in social environment impact primate gut microbiota composition/Experiment 1/Signature 2 |
| Changes in social environment impact primate gut microbiota composition/Experiment 2 |
| Changes in social environment impact primate gut microbiota composition/Experiment 3 |
| Changes in the gut microbiome associated with infliximab in patients with bipolar disorder/Experiment 1 |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder/Experiment 1 |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder/Experiment 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 1/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 1/Signature 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 2/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 2/Signature 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 3 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 3/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 3/Signature 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 4 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 4/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 5 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 5/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 6 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 6/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 6/Signature 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 7 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 7/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 8 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 8/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 9 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 9/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 9/Signature 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 10 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 10/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 10/Signature 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 11 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 11/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 11/Signature 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 12 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 12/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 12/Signature 2 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 13 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 13/Signature 1 |
| Changes in the nasopharyngeal and oropharyngeal microbiota in pediatric obstructive sleep apnea before and after surgery: a prospective study/Experiment 13/Signature 2 |
| Changes in the vaginal microbiota across a gradient of urbanization |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 1/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 1/Signature 2 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 2 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 2/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 3 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 3/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 4 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 4/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 5 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 5/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 6 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 6/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 6/Signature 2 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 7 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 7/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 8 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 8/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 9 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 9/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 10 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 10/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 11 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 11/Signature 1 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 11/Signature 2 |
| Changes in the vaginal microbiota across a gradient of urbanization/Experiment 12 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 1 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 3 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 6 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 7 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 8 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 9 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 10 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 1/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 2 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 2/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 2/Signature 2 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 3 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 3/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 3/Signature 2 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 4 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 4/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 4/Signature 2 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 5 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 5/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 5/Signature 2 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 6 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 6/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 6/Signature 2 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 7 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 7/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 8 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 8/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 8/Signature 2 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 9 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 9/Signature 1 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 9/Signature 2 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 10 |
| Characterization of the Gut and Skin Microbiome over Time in Young Children with IgE-Mediated Food Allergy/Experiment 10/Signature 1 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae) |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 1 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 1/Signature 1 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 1/Signature 2 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 2 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 2/Signature 1 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 2/Signature 2 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 3 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 3/Signature 1 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 3/Signature 2 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 4 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 4/Signature 1 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 4/Signature 2 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 5 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 5/Signature 1 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 5/Signature 2 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 6 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 6/Signature 1 |
| Characterization of the Tissue and Strain-Specific Microbiota of Anopheles funestus Giles (Diptera: Culicidae)/Experiment 6/Signature 2 |
| Community composition of cecal microbiota in commercial yellow broilers with high and low feed efficiencies |
| Community composition of cecal microbiota in commercial yellow broilers with high and low feed efficiencies/Experiment 1 |
| Community composition of cecal microbiota in commercial yellow broilers with high and low feed efficiencies/Experiment 1/Signature 1 |
| Community composition of cecal microbiota in commercial yellow broilers with high and low feed efficiencies/Experiment 1/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 9 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 13 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 14 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 15 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 17 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 18 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 21 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 22 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 23 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 1 |
| Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma/Experiment 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 1/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 1/Signature 2 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 2 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 2/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 2/Signature 2 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 3 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 3/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 3/Signature 2 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 4 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 4/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 4/Signature 2 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 5 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 5/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 5/Signature 2 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 6 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 6/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 6/Signature 2 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 7 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 7/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 7/Signature 2 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 8 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 8/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 9 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 9/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 10 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 10/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 11 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 11/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 12 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 12/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 13 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 13/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 14 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 14/Signature 1 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 15 |
| Decreased microbial co-occurrence network stability and SCFA receptor level correlates with obesity in African-origin women/Experiment 15/Signature 1 |
| Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns/Experiment 1 |
| Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice |
| Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice/Experiment 1 |
| Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice/Experiment 1/Signature 1 |
| Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice/Experiment 1/Signature 2 |
| Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 1 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 2 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 2/Signature 1 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 3 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 4 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 5 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 5/Signature 2 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 6 |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 1 |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 1/Signature 1 |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 2 |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 2/Signature 1 |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 2/Signature 2 |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 3 |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 3/Signature 1 |
| Differences in the microbial profiles of early stage endometrial cancers between Black and White women/Experiment 3/Signature 2 |
| Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients |
| Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients/Experiment 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 1/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 1/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 2/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 2/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 3 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 3/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 3/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 4 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 4/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 4/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 5 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 5/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 5/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 6 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 6/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 6/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 7 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 7/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 7/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 8 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 8/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 8/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 9 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 9/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 9/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 10 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 10/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 10/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 11 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 11/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 11/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 12 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 12/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 12/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 13 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 13/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 13/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 14 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 14/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 14/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 15 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 15/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 15/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 16 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 16/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 16/Signature 2 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 17 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 17/Signature 1 |
| Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia/Experiment 17/Signature 2 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 1 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 1/Signature 1 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 1/Signature 2 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 2 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 2/Signature 1 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 2/Signature 2 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 3 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 3/Signature 1 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 3/Signature 3 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 4 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 4/Signature 1 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 4/Signature 2 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 5 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 5/Signature 1 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 5/Signature 2 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 6 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 6/Signature 1 |
| Dynamic microbe and molecule networks in a mouse model of colitis-associated colorectal cancer/Experiment 6/Signature 2 |
| Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 1 |
| Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 2 |
| Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 1 |
| Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 2 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 1 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 2 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 3 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 2 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 3 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 4 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 5 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 6 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 7 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 8 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 9 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 10 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 11 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 12 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 13 |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1 |
| Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 4 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 1/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 1/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 2/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 2/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 3 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 3/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 3/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 4 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 4/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 4/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 5 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 5/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 5/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 6 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 6/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 6/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 7 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 7/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 7/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 8 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 8/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 9 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 9/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 9/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 10 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 10/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 10/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 11 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 11/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 11/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 12 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 12/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 12/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 13 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 13/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 13/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 14 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 14/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 14/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 15 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 15/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 15/Signature 2 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 16 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 16/Signature 1 |
| Environmental, socioeconomic, and health factors associated with gut microbiome species and strains in isolated Honduras villages/Experiment 16/Signature 2 |
| Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies |
| Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies/Experiment 1 |
| Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies/Experiment 1/Signature 1 |
| Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies/Experiment 1/Signature 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 3 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 4 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 5 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 6 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 7 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 8 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 9 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 10 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 11 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 12 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 13 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 14 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 15 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 16 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 17 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 18 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 19 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 20 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 21 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 22 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 23 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 24 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 25 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 1 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 1/Signature 1 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 1/Signature 2 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 2 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 2/Signature 1 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 2/Signature 2 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 3 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 3/Signature 1 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 3/Signature 2 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 4 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 4/Signature 1 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 5 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 5/Signature 1 |
| Faecal microbial transfer and complex carbohydrates mediate protection against COPD/Experiment 5/Signature 2 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 1 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 2 |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 1 |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 1/Signature 1 |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 2 |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 2/Signature 1 |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 2/Signature 2 |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 3 |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 3/Signature 1 |
| Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants/Experiment 3/Signature 2 |
| Freeze-drying can replace cold-chains for transport and storage of fecal microbiome samples |
| Freeze-drying can replace cold-chains for transport and storage of fecal microbiome samples/Experiment 1 |
| Freeze-drying can replace cold-chains for transport and storage of fecal microbiome samples/Experiment 1/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 1/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 1/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 2/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 2/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 3 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 3/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 3/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 4 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 4/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 4/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 5 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 5/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 5/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 6 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 6/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 6/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 7 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 7/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 7/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 8 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 8/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 8/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 9 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 9/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 9/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 10 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 10/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 10/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 11 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 11/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 11/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 12 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 12/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 12/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 13 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 13/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 13/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 14 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 14/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 14/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 15 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 15/Signature 1 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 15/Signature 2 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 16 |
| Gestational diabetes-related gut microbiome dysbiosis is not influenced by different Asian ethnicities and dietary interventions: a pilot study/Experiment 17 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 1/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 1/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 2/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 2/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 3 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 3/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 3/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 4 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 4/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 4/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 5 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 5/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 5/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 6 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 6/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 6/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 7 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 7/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 7/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 8 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 8/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 8/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 9 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 9/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 9/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 10 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 10/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 10/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 11 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 11/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 11/Signature 2 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 12 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 13 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 13/Signature 1 |
| Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women/Experiment 14 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 1/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 2/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 3 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 3/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 4 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 4/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 5/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 6/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 7/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 8/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 9 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 9/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 9/Signature 2 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10/Signature 1 |
| Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3/Experiment 10/Signature 2 |
| Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets |
| Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets/Experiment 1 |
| Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets/Experiment 2 |
| Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets/Experiment 2/Signature 1 |
| Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets/Experiment 2/Signature 2 |
| Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets/Experiment 4 |
| Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets/Experiment 4/Signature 1 |
| Gut flora and metabolism are altered in epilepsy and partially restored after ketogenic diets/Experiment 4/Signature 2 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 1 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 2 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 3 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 4 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 5 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 6 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 1/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 3 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 3/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 4 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 5 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 6 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 2 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 3 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 4 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 4/Signature 2 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 5 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 6 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 6/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 7 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 7/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 8 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 8/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 9 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 9/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 10 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 10/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 11 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 11/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 12 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 12/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 13 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 13/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 14 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 14/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 15 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 15/Signature 1 |
| Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 5 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 1 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 1/Signature 1 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 1/Signature 2 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 2 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 2/Signature 1 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 2/Signature 2 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 3 |
| Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment/Experiment 3/Signature 1 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5 |
| Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 2 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 3 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 4 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 5 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 6 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 7 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 1/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 1/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 2/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 2/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 3 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 3/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 3/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 4 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 4/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 4/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 5 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 5/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 5/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 6 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 6/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 6/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 7 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 7/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 7/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 8 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 8/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 8/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 9 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 9/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 9/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 10 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 10/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 10/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 11 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 11/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 11/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 12 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 12/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 12/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 13 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 13/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 13/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 14 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 14/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 14/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 15 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 15/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 15/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 16 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 16/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 16/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 17 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 17/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 17/Signature 2 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 18 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 18/Signature 1 |
| Gut microbiomes of agropastoral children from the Adadle region of Ethiopia reflect their unique dietary habits/Experiment 18/Signature 2 |
| Gut microbiota alterations in response to sleep length among African-origin adults |
| Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 1 |
| Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 2 |
| Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 3 |
| Gut microbiota changes in patients with autism spectrum disorders |
| Gut microbiota changes in patients with autism spectrum disorders/Experiment 1 |
| Gut microbiota changes in patients with autism spectrum disorders/Experiment 1/Signature 1 |
| Gut microbiota changes in patients with autism spectrum disorders/Experiment 1/Signature 2 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 1 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 1/Signature 1 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 2 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 2/Signature 1 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 3 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 3/Signature 1 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 4 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 4/Signature 1 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 5 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 5/Signature 1 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 5/Signature 2 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 6 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 6/Signature 1 |
| Gut microbiota-derived LCA mediates the protective effect of PEDV infection in piglets/Experiment 6/Signature 2 |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 1/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 2 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 2/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 3 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 3/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 4 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 4/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 5 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 5/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 6 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 6/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 7 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 7/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 8 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 8/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 9 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 9/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 10 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 10/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 11 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 11/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 12/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 13 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 13/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 13/Signature 2 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 14 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 14/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 14/Signature 2 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 15 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 15/Signature 1 |
| Higher Risk of Stroke Is Correlated With Increased Opportunistic Pathogen Load and Reduced Levels of Butyrate-Producing Bacteria in the Gut/Experiment 15/Signature 2 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 1 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 1/Signature 1 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 1/Signature 2 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 2 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 2/Signature 1 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 2/Signature 2 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 3 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 3/Signature 1 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 3/Signature 2 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 4 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 4/Signature 2 |
| Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial/Experiment 4/Signature 3 |
| Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats/Experiment 2 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 1 |
| Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 1 |
| Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 22 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 23 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 24 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 36 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 37 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 38 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 39 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 40 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 41 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 42 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 43 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 44 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 45 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 46 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 47 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 48 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 49 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 50 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 51 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 52 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 53 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 54 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 55 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 56 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 57 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 58 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 59 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 60 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 61 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 62 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 63 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 64 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 65 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 66 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 67 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 68 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 69 |
| Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 2 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 3 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 4 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 5 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 6 |
| Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α and peritoneal fluid flora were associated with infertility in patients with endometriosis/Experiment 1 |
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 2 |
| Insights into the gut microbiome of vitiligo patients from India |
| Insights into the gut microbiome of vitiligo patients from India/Experiment 1 |
| Insights into the gut microbiome of vitiligo patients from India/Experiment 1/Signature 1 |
| Insights into the gut microbiome of vitiligo patients from India/Experiment 1/Signature 2 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 2 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3 |
| Integrating respiratory microbiome and host immune response through machine learning for respiratory tract infection diagnosis |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2 |
| Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 1 |
| Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1 |
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3 |
| Intestinal permeability before and after albendazole treatment in low and high socioeconomic status schoolchildren in Makassar, Indonesia |
| Intestinal permeability before and after albendazole treatment in low and high socioeconomic status schoolchildren in Makassar, Indonesia/Experiment 1 |
| Intestinal permeability before and after albendazole treatment in low and high socioeconomic status schoolchildren in Makassar, Indonesia/Experiment 1/Signature 1 |
| Intestinal permeability before and after albendazole treatment in low and high socioeconomic status schoolchildren in Makassar, Indonesia/Experiment 1/Signature 2 |
| Intestinal permeability before and after albendazole treatment in low and high socioeconomic status schoolchildren in Makassar, Indonesia/Experiment 2 |
| Intestinal permeability before and after albendazole treatment in low and high socioeconomic status schoolchildren in Makassar, Indonesia/Experiment 2/Signature 1 |
| Intestinal permeability before and after albendazole treatment in low and high socioeconomic status schoolchildren in Makassar, Indonesia/Experiment 2/Signature 2 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 1/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 1/Signature 2 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 2 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 2/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 2/Signature 2 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 3 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 3/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 4 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 4/Signature 1 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 5 |
| Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy/Experiment 5/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 1 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 2 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 2/Signature 1 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 2/Signature 2 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 3 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 3/Signature 1 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 3/Signature 2 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 4 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 4/Signature 1 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 4/Signature 2 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 5 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 5/Signature 1 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 5/Signature 2 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 6 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 6/Signature 2 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 7 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 7/Signature 1 |
| Large-scale metagenomic analysis of oral microbiomes reveals markers for autism spectrum disorders/Experiment 7/Signature 2 |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2 |
| Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients |
| Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients/Experiment 1 |
| Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients/Experiment 1/Signature 1 |
| Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients/Experiment 1/Signature 2 |
| Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients/Experiment 2 |
| Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients/Experiment 2/Signature 1 |
| Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients/Experiment 2/Signature 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 3 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 4 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 1/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 1/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 2/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 2/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 3 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 3/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 3/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 4 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 4/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 4/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 5 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 5/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 5/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 6 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 6/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 6/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 7 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 7/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 7/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 8 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 8/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 8/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 9 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 9/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 9/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 10 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 10/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 10/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 11 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 11/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 11/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 12 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 12/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 12/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 13 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 13/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 13/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 14 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 14/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 14/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 15 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 15/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 15/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 16 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 16/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 16/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 17 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 17/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 17/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 18 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 18/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 18/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 19 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 19/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 19/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 20 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 20/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 20/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 21 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 21/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 21/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 22 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 22/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 22/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 23 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 23/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 23/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 24 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 24/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 24/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 25 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 25/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 25/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 26 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 26/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 26/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 27 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 27/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 27/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 28 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 28/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 28/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 29 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 29/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 29/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 30 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 30/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 30/Signature 2 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 31 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 31/Signature 1 |
| Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 31/Signature 2 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1 |
| Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 6 |
| Lung microbiome of stable and exacerbated COPD patients in Tshwane, South Africa |
| Lung microbiome of stable and exacerbated COPD patients in Tshwane, South Africa/Experiment 1 |
| Lung microbiome of stable and exacerbated COPD patients in Tshwane, South Africa/Experiment 1/Signature 1 |
| Major urinary protein (Mup) gene family deletion drives sex-specific alterations on the house mouse gut microbiota/Experiment 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2 |
| Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 3/Signature 2 |
| Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 3/Signature 3 |
| Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations/Experiment 3/Signature 4 |
| Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation/Experiment 1 |
| Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens |
| Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 1 |
| Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 1/Signature 1 |
| Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 1/Signature 2 |
| Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 2 |
| Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 2/Signature 1 |
| Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens/Experiment 2/Signature 2 |
| Metagenomic Profiling of Ocular Surface Microbiome Changes in Meibomian Gland Dysfunction |
| Metagenomic Profiling of Ocular Surface Microbiome Changes in Meibomian Gland Dysfunction/Experiment 1 |
| Metagenomic Profiling of Ocular Surface Microbiome Changes in Meibomian Gland Dysfunction/Experiment 1/Signature 1 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 1 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 1/Signature 1 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 1/Signature 2 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 2 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 2/Signature 1 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 2/Signature 2 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 3 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 3/Signature 1 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 3/Signature 2 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 4 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 4/Signature 1 |
| Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection/Experiment 4/Signature 2 |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese/Experiment 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1 |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 1/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 2/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 3 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 3/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 4 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 4/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 5 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 5/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 6 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 6/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 7 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 7/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 7/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 8 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 8/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 8/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 9 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 9/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 9/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 10 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 10/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 10/Signature 2 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 11 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 11/Signature 1 |
| Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China/Experiment 11/Signature 2 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 1 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 2 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 3 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 4 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 5 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 6 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 7 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 8 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 9 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 10 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 11 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 12 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 13 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 14 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2 |
| Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 1/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 1/Signature 2 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 2 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 2/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 3 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 3/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 4 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 4/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 5 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 5/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 6 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 6/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 6/Signature 2 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 7 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 7/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 7/Signature 2 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 8 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 8/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 9 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 9/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 10 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 10/Signature 1 |
| Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study/Experiment 10/Signature 2 |
| Microbiota assembly, structure, and dynamics among Tsimane horticulturalists of the Bolivian Amazon |
| Microbiota assembly, structure, and dynamics among Tsimane horticulturalists of the Bolivian Amazon/Experiment 1 |
| Microbiota assembly, structure, and dynamics among Tsimane horticulturalists of the Bolivian Amazon/Experiment 1/Signature 1 |
| Microbiota assembly, structure, and dynamics among Tsimane horticulturalists of the Bolivian Amazon/Experiment 1/Signature 2 |
| Microbiota assembly, structure, and dynamics among Tsimane horticulturalists of the Bolivian Amazon/Experiment 2/Signature 1 |
| Microbiota assembly, structure, and dynamics among Tsimane horticulturalists of the Bolivian Amazon/Experiment 2/Signature 2 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2 |
| Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis |
| Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 1 |
| Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 1/Signature 1 |
| Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 1/Signature 2 |
| Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 2 |
| Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 2/Signature 1 |
| Microbiota from alginate oligosaccharide-dosed mice successfully mitigated small intestinal mucositis/Experiment 2/Signature 2 |
| Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 4 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 1/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 1/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 2/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 2/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 3 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 3/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 3/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 4 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 4/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 4/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 5 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 5/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 5/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 6 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 6/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 6/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 7 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 7/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 7/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 8 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 8/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 8/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 9 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 9/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 9/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 10 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 10/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 10/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 11 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 11/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 11/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 12 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 12/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 12/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 13 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 13/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 14 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 14/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 14/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 15 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 15/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 15/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 16 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 16/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 16/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 17 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 17/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 17/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 18 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 18/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 19 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 19/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 19/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 20 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 20/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 21 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 21/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 22 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 22/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 22/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 23 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 23/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 23/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 24 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 24/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 24/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 25 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 25/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 25/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 26 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 26/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 27 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 27/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 27/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 28 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 28/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 28/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 29 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 29/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 29/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 30 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 30/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 30/Signature 2 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 31 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 31/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 32 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 32/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 33 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 33/Signature 1 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 34 |
| Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis/Experiment 34/Signature 1 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1 |
| More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota |
| More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota/Experiment 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 2 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups/Experiment 3 |
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients/Experiment 1 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 1 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 1/Signature 1 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 1/Signature 2 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 2 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 2/Signature 1 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 3 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 3/Signature 1 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 3/Signature 2 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 4 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 4/Signature 1 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 5 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 5/Signature 1 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 6 |
| Nepali oral microbiomes reflect a gradient of lifestyles from traditional to industrialized/Experiment 6/Signature 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 1/Signature 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 1/Signature 2 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 2 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 2/Signature 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 2/Signature 2 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 3 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 3/Signature 1 |
| Ocular surface microbiota in patients with varying degrees of dry eye severity/Experiment 3/Signature 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 1/Signature 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 1/Signature 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 2/Signature 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 2/Signature 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 3 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 3/Signature 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 3/Signature 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 4 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 4/Signature 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 4/Signature 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 5 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 5/Signature 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 5/Signature 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 6 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 6/Signature 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 6/Signature 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 7 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 7/Signature 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 7/Signature 2 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 8 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 8/Signature 1 |
| Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease/Experiment 8/Signature 2 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 2 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 3 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 4 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 5 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 6 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 3 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 4 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 5 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 6 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 7 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 8 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 9 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 10 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 11 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 12 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 13 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 14 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 15 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 16 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 17 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 18 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 19 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 20 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 21 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 22 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 23 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 24 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 25 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 26 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 27 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 28 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 29 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 30 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 31 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 3 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 4 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 5 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 6 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 7 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 8 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 9 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 10 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 11 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 12 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 13 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 14 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 15 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 16 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 17 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 1/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 2 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 2/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 3 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 3/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 4 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 4/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 5 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 5/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 6 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 6/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 7 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 7/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 8 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 8/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 9 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 9/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 10 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 10/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 10/Signature 2 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 11 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 11/Signature 1 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 11/Signature 2 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 12 |
| Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study/Experiment 12/Signature 1 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 1 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 1/Signature 1 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 1/Signature 2 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 2 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 2/Signature 1 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 2/Signature 2 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 3 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 3/Signature 1 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 3/Signature 2 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 4 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 4/Signature 1 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 4/Signature 2 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 5 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 5/Signature 1 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 5/Signature 2 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 6 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 6/Signature 1 |
| Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments/Experiment 6/Signature 2 |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 1/Signature 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 1/Signature 2 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 2 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 2/Signature 1 |
| Parasite-Derived Excretory-Secretory Products Alleviate Gut Microbiota Dysbiosis and Improve Cognitive Impairment Induced by a High-Fat Diet/Experiment 2/Signature 2 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1 |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1 |
| Previse preterm birth in early pregnancy through vaginal microbiome signatures using metagenomics and dipstick assays |
| Previse preterm birth in early pregnancy through vaginal microbiome signatures using metagenomics and dipstick assays/Experiment 1 |
| Previse preterm birth in early pregnancy through vaginal microbiome signatures using metagenomics and dipstick assays/Experiment 1/Signature 1 |
| Previse preterm birth in early pregnancy through vaginal microbiome signatures using metagenomics and dipstick assays/Experiment 1/Signature 2 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1 |
| Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing |
| Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 1 |
| Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 1/Signature 1 |
| Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing/Experiment 1/Signature 2 |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1 |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1 |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1 |
| Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease/Experiment 1 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 2 |
| Resilience of the respiratory microbiome in controlled adult RSV challenge study/Experiment 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3 |
| SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition/Experiment 1 |
| Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas |
| Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 1 |
| Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 2 |
| Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 2/Signature 1 |
| Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 2/Signature 2 |
| Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 3/Signature 1 |
| Seasonal shifts in the gut microbiome indicate plastic responses to diet in wild geladas/Experiment 4/Signature 1 |
| Shift in skin microbiota of Western European women across aging/Experiment 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 1/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 1/Signature 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 2/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 3 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 3/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 3/Signature 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 4 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 4/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 4/Signature 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 5 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 5/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 5/Signature 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 6 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 6/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 6/Signature 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 7 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 7/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 8 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 8/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 8/Signature 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 9 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 9/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 9/Signature 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 10 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 10/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 10/Signature 2 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 11 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 11/Signature 1 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 12 |
| Shifts in microbial diversity, composition, and functionality in the gut and genital microbiome during a natural SIV infection in vervet monkeys/Experiment 12/Signature 1 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1 |
| Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder/Experiment 1 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 1 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 2 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 3 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 4 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 5 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 6 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 7 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 8 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 9 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 10 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 11 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 12 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 13 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 14 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 15 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 16 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 17 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 18 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 19 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 20 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 21 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 22 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 3 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 4 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 5 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 6 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 7 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 8 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 9 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 10 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 11 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 12 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 13 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 14 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 15 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 16 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 17 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 18 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 19 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 20 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 21 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 22 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 23 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 24 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 25 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2 |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year/Experiment 1 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1 |
| Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 3 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 4 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 5 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 6 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 7 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 8 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 9 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 10 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 11 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 12 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 13 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 14 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 15 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 16 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 17 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 18 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 19 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 20 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 21 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 22 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 23 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 24 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 25 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 26 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 27 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 28 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 29 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 30 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 31 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 32 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 33 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 34 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 35 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 36 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 37 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 38 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 39 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 40 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 41 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 42 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 43 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 44 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 45 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 46 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 47 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 48 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 49 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 50 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 51 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 52 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 53 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 54 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 55 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 56 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 57 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 58 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 59 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 60 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 61 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 62 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 63 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 64 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 65 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 66 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 67 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 68 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 69 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 70 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 71 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 72 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 73 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 74 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 75 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 76 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 77 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 78 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 79 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 80 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 81 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 82 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 83 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 84 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 85 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 86 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 87 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 88 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 89 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 90 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 91 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 92 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 93 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 94 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 95 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 96 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 97 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 98 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 99 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 100 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 101 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 102 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 103 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 104 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 105 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 106 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 107 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 108 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 109 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 110 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 111 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 112 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 113 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 114 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 115 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 116 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 117 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 118 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 119 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 120 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 121 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 122 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 123 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 124 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 125 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 126 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 127 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 128 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 129 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 130 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 131 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 132 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 133 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 134 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 135 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 136 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 137 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 138 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 139 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 140 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 141 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 142 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 143 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 144 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 145 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 146 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 147 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 148 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 149 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 150 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 151 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 152 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 153 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 154 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 155 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 156 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 157 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 158 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 159 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 160 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 161 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 162 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 163 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 164 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 165 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 166 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 167 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 168 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 169 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 170 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 171 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 172 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 173 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 174 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 175 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 176 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 177 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 178 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 179 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 180 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 181 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 182 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 183 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 184 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 185 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 186 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 187 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 188 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 189 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 190 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 191 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 192 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 193 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 194 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 195 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 196 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 197 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 198 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 199 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 200 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 201 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 202 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 203 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 204 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 205 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 206 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 207 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 208 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 209 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 210 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 211 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 212 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 213 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 214 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 215 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 216 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 1 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 1/Signature 2 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 1/Signature 3 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 3 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 3/Signature 1 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 3/Signature 2 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 4 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 4/Signature 1 |
| Structural changes in the oral microbiome of the adolescent patients with moderate or severe dental fluorosis/Experiment 4/Signature 2 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 1 |
| Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 2 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 1/Signature 2 |
| Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 2/Signature 1 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 1/Signature 2 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 2/Signature 1 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 2/Signature 2 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 3/Signature 1 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 3/Signature 2 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 4/Signature 1 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 4/Signature 2 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 5/Signature 1 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 6/Signature 1 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 6/Signature 2 |
| Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease/Experiment 7/Signature 1 |
| Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease/Experiment 1/Signature 2 |
| Reduced microbiome alpha diversity in young patients with ADHD |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 1 |
| Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 2 |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder |
| Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 1 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 1 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 2 |
| Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2/Signature 1 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1/Signature 1 |
| Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2/Signature 1 |
| Linking long-term dietary patterns with gut microbial enterotypes |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 2 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 1 |
| Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 2 |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 1 |
| Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 2 |
| Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway/Experiment 1/Signature 2 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1/Signature 1 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 1 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 2 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 1 |
| Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 2 |
| Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3/Signature 2 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 1 |
| Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 2 |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 1 |
| Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 2 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 1 |
| Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 2 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 1 |
| Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 2 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1/Signature 1 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 1 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 2 |
| Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3/Signature 1 |
| Shift in skin microbiota of Western European women across aging |
| Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 1 |
| Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 2 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1/Signature 1 |
| Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2/Signature 1 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 1 |
| Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 2 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3/Signature 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4/Signature 1 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 1 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 2 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 3 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 4 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 1 |
| Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 2 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2/Signature 1 |
| Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 2/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 2 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 1 |
| Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 2 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 1 |
| Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 2 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 1 |
| Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 2 |
| Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 3/Signature 2 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 1 |
| Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 2 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1/Signature 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2/Signature 1 |
| Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 2/Signature 2 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 2 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 1 |
| Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 2 |
| Influence of cigarette smoking on the human duodenal mucosa-associated microbiota |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 1 |
| Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 2 |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children |
| Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1/Signature 1 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 1 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 2 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 2 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 1 |
| Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 2 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 1 |
| Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 2 |
| Oral microbiome and obesity in a large study of low-income and African-American populations |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1/Signature 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 1 |
| Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 2 |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year |
| Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year/Experiment 1/Signature 1 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 1 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 2 |
| Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2/Signature 1 |
| The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome |
| High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1/Signature 2 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 1 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 2 |
| Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4/Signature 1 |
| Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 4/Signature 2 |
| Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 1 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 2 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 1 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 2 |
| SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 1 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 2 |
| Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 3 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults |
| Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 2/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 2 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 1 |
| Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 2 |
| Study 501 |
| Study 501/Experiment 1 |
| Study 501/Experiment 1/Signature 1 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 1 |
| Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 2 |
| Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2/Signature 2 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 1 |
| Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 2 |
| The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls/Experiment 2/Signature 1 |
| Analysis of the Conjunctival Microbiome in Patients with Atopic Keratoconjunctivitis and Healthy Individuals/Experiment 1/Signature 3 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1/Signature 3 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 1 |
| Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 2 |
| Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1/Signature 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 1/Signature 2 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2/Signature 1 |
| Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer/Experiment 2/Signature 2 |
| Body site-typical microbiome signatures for children/Experiment 2/Signature 1 |
| Body site-typical microbiome signatures for children/Experiment 2/Signature 2 |
| The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial |
| Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 2/Signature 1 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 1 |
| Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 2 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 1 |
| Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 2 |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 1 |
| Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 2 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 1 |
| Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 2 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 1 |
| Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 2 |
| Gut microbiota: impacts on gastrointestinal cancer immunotherapy/Experiment 1/Signature 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 1/Signature 2 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 2/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 3/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 5/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 6/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 7/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 9/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 12/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 13/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 14/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 16/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 17/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 18/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 19/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 21/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 22/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 23/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 24/Signature 1 |
| Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial/Experiment 25/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 1/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 2/Signature 2 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3/Signature 1 |
| Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells/Experiment 3/Signature 2 |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1/Signature 1 |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1/Signature 2 |
| The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder/Experiment 4/Signature 2 |
| The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 2/Signature 2 |
| Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 1/Signature 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 2/Signature 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 3/Signature 1 |
| Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria/Experiment 2/Signature 1 |
| Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria/Experiment 2/Signature 2 |
| Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects |
| Study 783 |
| Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 7/Signature 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1/Signature 1 |
| Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease/Experiment 1/Signature 2 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1/Signature 1 |
| Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets/Experiment 1/Signature 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 1/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 1/Signature 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 6/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 6/Signature 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 7/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 8/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 9/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 10/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 11/Signature 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 12/Signature 1 |
| Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese/Experiment 1/Signature 1 |
| Resilience of the respiratory microbiome in controlled adult RSV challenge study |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1/Signature 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2/Signature 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3/Signature 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3/Signature 2 |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1/Signature 1 |
| Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome/Experiment 1/Signature 2 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 1/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 2/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 3/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 4/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 5/Signature 1 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 5/Signature 2 |
| Oral lesion and microbiome diversity in COVID-19 hospitalized patients/Experiment 6/Signature 1 |
| Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 1/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 2/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 3/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 4/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 5/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 6/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 7/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 8/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 9/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 10/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 11/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 12/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 13/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 14/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 15/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 16/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 17/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 18/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 19/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 20/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 21/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 25/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 26/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 27/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 28/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 29/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 30/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 31/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 32/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 33/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 34/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 35/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 36/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 36/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 37/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 37/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 38/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 38/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 39/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 39/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 40/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 40/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 41/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 41/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 42/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 42/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 43/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 43/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 44/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 44/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 45/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 45/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 49/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 49/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 50/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 50/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 51/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 51/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 52/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 52/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 53/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 53/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 54/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 54/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 55/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 55/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 56/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 56/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 57/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 57/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 58/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 58/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 59/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 59/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 60/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 60/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 61/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 61/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 62/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 62/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 63/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 63/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 64/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 64/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 65/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 65/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 66/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 66/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 67/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 67/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 68/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 68/Signature 2 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 69/Signature 1 |
| Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition/Experiment 69/Signature 2 |
| Microbial communities associated with honey bees in Brazil and in the United States |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1/Signature 1 |
| Microbial communities associated with honey bees in Brazil and in the United States/Experiment 1/Signature 2 |
| Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls/Experiment 1/Signature 2 |
| Study 919/Experiment 1 |
| Study 919/Experiment 1/Signature 1 |
| Study 919/Experiment 1/Signature 2 |
| Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 6/Signature 1 |
| More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota/Experiment 1/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 1/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 1/Signature 2 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 2/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 2/Signature 2 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 3/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 3/Signature 2 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 7/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 7/Signature 2 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 8/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 8/Signature 2 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 9/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 9/Signature 2 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 10/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 11/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 12/Signature 1 |
| Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs/Experiment 13/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 1/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 2/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 5/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 5/Signature 2 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 6/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 6/Signature 3 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 7/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 8/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 8/Signature 2 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 9/Signature 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 9/Signature 2 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 10/Signature 1 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 1/Signature 1 |
| Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1/Signature 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 1/Signature 2 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 2/Signature 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3/Signature 1 |
| Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to Blautia Genus: Evidence From Feces, Blood, and Brain/Experiment 3/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 1/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 2/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 2/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 3/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 4/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 4/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 5/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 5/Signature 2 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 6/Signature 1 |
| Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood/Experiment 6/Signature 2 |
| Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder |
| Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder/Experiment 1/Signature 1 |
| Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder/Experiment 1/Signature 2 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 1/Signature 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 2/Signature 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 3/Signature 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 3/Signature 2 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 4/Signature 1 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 1/Signature 1 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 1/Signature 2 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 2/Signature 1 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 2/Signature 2 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 1/Signature 1 |
| Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis/Experiment 1/Signature 2 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 1/Signature 1 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 1/Signature 2 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 2/Signature 1 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 2/Signature 2 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 3/Signature 1 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 3/Signature 2 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 4/Signature 1 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 4/Signature 2 |
| Current levels of microplastic pollution impact wild seabird gut microbiomes/Experiment 5/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 1/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 1/Signature 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 2/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 2/Signature 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 3/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 3/Signature 2 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 4/Signature 1 |
| Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease/Experiment 4/Signature 2 |
| Study 1030 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 1/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 1/Signature 2 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 3/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 4/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 5/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 6/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 8/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 9/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 10/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 11/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 12/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 13/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 13/Signature 2 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 14/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 15/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 16/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 16/Signature 2 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 17/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 18/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 19/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 20/Signature 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 21/Signature 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 1/Signature 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 1/Signature 2 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 2/Signature 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 2/Signature 2 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 3/Signature 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 3/Signature 2 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 4/Signature 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 4/Signature 2 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 5/Signature 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 5/Signature 2 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 6/Signature 1 |
| Increased diversity of a cervical microbiome associates with cervical cancer/Experiment 6/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 33/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 33/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 34/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 34/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 35/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 35/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 36/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 36/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 37/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 37/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 38/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 38/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 39/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 39/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 40/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 40/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 41/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 41/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 42/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 42/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 43/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 43/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 44/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 44/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 45/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 45/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 46/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 46/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 47/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 47/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 48/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 48/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 49/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 49/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 50/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 50/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 51/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 51/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 52/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 52/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 53/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 53/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 54/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 54/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 55/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 55/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 56/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 56/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 57/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 57/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 58/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 58/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 62/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 62/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 64/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 64/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 65/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 65/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 66/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 66/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 67/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 67/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 68/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 68/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 69/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 69/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 70/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 70/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 71/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 71/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 72/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 72/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 109/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 109/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 110/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 110/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 111/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 111/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 112/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 112/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 113/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 113/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 114/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 114/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 115/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 115/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 116/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 116/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 117/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 117/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 118/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 118/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 119/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 119/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 120/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 120/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 121/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 121/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 122/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 122/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 123/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 123/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 124/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 124/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 125/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 125/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 126/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 126/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 127/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 127/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 128/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 128/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 129/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 129/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 130/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 130/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 131/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 131/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 132/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 132/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 133/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 133/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 134/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 134/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 135/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 135/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 136/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 136/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 137/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 137/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 138/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 138/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 139/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 139/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 140/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 140/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 141/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 141/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 142/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 142/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 143/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 143/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 144/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 144/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 145/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 145/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 146/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 146/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 147/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 147/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 148/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 148/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 149/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 149/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 150/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 150/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 151/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 151/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 152/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 152/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 153/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 153/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 154/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 154/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 155/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 155/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 156/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 156/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 157/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 157/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 158/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 158/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 159/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 159/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 160/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 160/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 161/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 161/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 162/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 162/Signature 2 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 207/Signature 1 |
| Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns/Experiment 207/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 1/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 2/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 2/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 3/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 3/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 4/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 4/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 5/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 5/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 6/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 6/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 7/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 7/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 8/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 8/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 9/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 9/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 10/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 10/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 11/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 11/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 12/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 12/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 13/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 13/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 14/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 14/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 15/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 16/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 17/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 17/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 18/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 19/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 19/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 20/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 21/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 22/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 23/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 24/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 24/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 25/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 26/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 27/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 28/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 29/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 30/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 31/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 31/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 32/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 33/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 34/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 35/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 36/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 37/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 37/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 38/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 39/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 40/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 40/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 41/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 42/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 43/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 44/Signature 1 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 44/Signature 2 |
| A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs/Experiment 45/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 1/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 1/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 2/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 2/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 3/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 3/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 4/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 4/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 5/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 5/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 6/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 6/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 7/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 7/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 8/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 8/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 9/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 9/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 10/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 10/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 11/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 12/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 12/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 13/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 13/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 14/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 14/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 15/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 15/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 16/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 16/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 17/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 17/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 18/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 18/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 19/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 19/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 20/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 21/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 21/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 22/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 22/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 23/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 24/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 24/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 25/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 26/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 26/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 27/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 27/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 28/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 28/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 29/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 29/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 30/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 30/Signature 2 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 31/Signature 1 |
| Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe/Experiment 31/Signature 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4/Signature 1 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 4/Signature 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5/Signature 1 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 5/Signature 2 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 6/Signature 1 |
| Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension/Experiment 6/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 1/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 1/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 2/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 2/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 3/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 3/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 4/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 4/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 5/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 5/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 6/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 6/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 7/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 7/Signature 2 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 8/Signature 1 |
| Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium/Experiment 8/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 9/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 15/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20/Signature 1 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20/Signature 2 |
| Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 23/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 1/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 1/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 2/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 2/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 3/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 3/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 4/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 4/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 5/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 5/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 6/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 6/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 7/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 7/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 8/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 8/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 9/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 10/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 10/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 11/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 11/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 12/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 12/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 13/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 14/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 14/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 15/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 16/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 17/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 18/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 18/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 19/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 19/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 20/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 20/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 21/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 21/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 22/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 22/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 23/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 23/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 24/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 24/Signature 2 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 25/Signature 1 |
| Signatures within the esophageal microbiome are associated with host genetics, age, and disease/Experiment 25/Signature 2 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 1/Signature 1 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 1/Signature 2 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 2/Signature 1 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 2/Signature 2 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 3/Signature 1 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 3/Signature 2 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 4/Signature 1 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 4/Signature 2 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 5/Signature 1 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 5/Signature 2 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 6/Signature 1 |
| Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age/Experiment 6/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 1/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 1/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 2/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 2/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 3/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 3/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 4/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 4/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 5/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 5/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 6/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 6/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 7/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 7/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 8/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 8/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 9/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 9/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 10/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 10/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 11/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 11/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 12/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 12/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 13/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 13/Signature 2 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 14/Signature 1 |
| Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study/Experiment 14/Signature 2 |
| Changes in the gut microbiome associated with infliximab in patients with bipolar disorder |
| Study 1098 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 1/Signature 1 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 1/Signature 2 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 2/Signature 1 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 3/Signature 1 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 4/Signature 1 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 6/Signature 1 |
| Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study/Experiment 6/Signature 2 |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder/Experiment 1/Signature 1 |
| Changes in the Gut Microbiota of Children with Autism Spectrum Disorder/Experiment 1/Signature 2 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 1/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 2/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 4/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 5/Signature 1 |
| Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease/Experiment 5/Signature 2 |
| Study 1112 |
| Study 1116 |
| Study 1120 |
| Study 1128 |
| Study 1129 |
| Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters |
| Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 1/Signature 1 |
| Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 1/Signature 2 |
| Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 2/Signature 1 |
| Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters/Experiment 2/Signature 2 |
| Study 1134 |
| Study 1136 |
| Study 1137 |
| Study 1138 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 1/Signature 1 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 1/Signature 2 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 2/Signature 2 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 5/Signature 1 |
| Differences in salivary microbiome among children with tonsillar hypertrophy and/or adenoid hypertrophy/Experiment 6/Signature 1 |
| Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke |
| Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 1/Signature 1 |
| Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 1/Signature 4 |
| Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 2/Signature 1 |
| Imbalance of Microbacterial Diversity Is Associated with Functional Prognosis of Stroke/Experiment 2/Signature 2 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 1/Signature 1 |
| Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders/Experiment 1/Signature 2 |
| Study 1153 |
| Study 1155 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 1/Signature 1 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 1/Signature 2 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 2/Signature 1 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 2/Signature 2 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 3/Signature 1 |
| Dysbiosis of Gut Microbiota Is an Independent Risk Factor of Stroke-Associated Pneumonia: A Chinese Pilot Study/Experiment 3/Signature 2 |
| Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 1/Signature 1 |
| Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 1/Signature 2 |
| Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 2/Signature 1 |
| Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 3/Signature 1 |
| Gut microbiota alterations in response to sleep length among African-origin adults/Experiment 3/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 2/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 3/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 4/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 4/Signature 2 |
| Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents/Experiment 1/Signature 1 |
| Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents/Experiment 1/Signature 2 |
| Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study |
| Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 1/Signature 1 |
| Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 1/Signature 2 |
| Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 2/Signature 1 |
| Dysbiosis of Gut Microbiota and Short-Chain Fatty Acids in Encephalitis: A Chinese Pilot Study/Experiment 2/Signature 2 |
| Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients/Experiment 1/Signature 1 |
| Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients/Experiment 1/Signature 2 |
| Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients/Experiment 1/Signature 3 |
| Study 1164 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 1/Signature 1 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 1/Signature 2 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 1/Signature 3 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 2/Signature 1 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 2/Signature 2 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 2/Signature 3 |
| Faecal microbiota and cytokine profiles of rural Cambodian infants linked to diet and diarrhoeal episodes/Experiment 2/Signature 4 |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 1/Signature 1 |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 1/Signature 2 |
| Antenatal gut microbiome profiles and effect on pregnancy outcome in HIV infected and HIV uninfected women in a resource limited setting/Experiment 3/Signature 2 |
| Study 1171 |
| Left atrial geometry and outcome of atrial fibrillation ablation: results from the multicentre LAGO-AF study |
| The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 1/Signature 1 |
| The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 2/Signature 1 |
| The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 3/Signature 1 |
| A case report of malignant primary pericardial mesothelioma with atypical imaging appearance: multimodality imaging with histopathological correlation |
| Study 1199 |
| Study 1218/Experiment 1/Signature 1 |
| Study 1218/Experiment 1/Signature 2 |
| Study 1218/Experiment 6/Signature 1 |
| Study 1235/Experiment 1/Signature 1 |
| Study 1235/Experiment 1/Signature 2 |
| Study 1235/Experiment 2/Signature 1 |
| Study 1235/Experiment 2/Signature 2 |
| Study 1235/Experiment 3/Signature 1 |
| Study 1235/Experiment 3/Signature 2 |
| Study 1235/Experiment 4/Signature 1 |
| Study 1235/Experiment 4/Signature 2 |
| Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1 |
| Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3 |
| Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4 |
| Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 7 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 3 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 4 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 5 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 6 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 7 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 7/Signature 2 |
| Study 1160/Experiment 8 |
| Study 1160/Experiment 9 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 10 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 10/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 10/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 11 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 11/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 11/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 12 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 12/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 12/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 13 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 13/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 14 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 14/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 14/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 15 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 15/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 15/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 16 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 16/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 16/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 17 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 17/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 17/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 18 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 18/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 18/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 19 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 19/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 19/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 20 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 20/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 20/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 21 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 21/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 21/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 22 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 22/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 22/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 23 |
| Study 1160/Experiment 23/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 23/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 24 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 24/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 24/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 25 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 25/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 25/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 26 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 26/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 26/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 27 |
| Study 1160/Experiment 27/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 27/Signature 2 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 28 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 28/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 29 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 29/Signature 1 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 30 |
| Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome/Experiment 30/Signature 1 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 1 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 2 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 3 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 4 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 5 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 6 |
| Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 7 |
| Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3 |
| The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4 |
| The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial/Experiment 1 |
| The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 4 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 1 |
| The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age/Experiment 2 |
| The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population |
| The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 1 |
| The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 2 |
| The gut microbial composition in polycystic ovary syndrome with insulin resistance: findings from a normal-weight population/Experiment 3 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 1 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 2 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 3 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 4 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 5 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 6 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 7 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 8 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 9 |
| The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 10 |
| The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome/Experiment 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 1/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 1/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 2/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 2/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 3 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 3/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 4 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 4/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 4/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 5 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 5/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 5/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 6 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 6/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 6/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 7 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 7/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 8 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 8/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 9 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 9/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 9/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 10 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 10/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 11 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 11/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 11/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 12 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 12/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 13 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 13/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 13/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 14 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 14/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 15 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 15/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 15/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 16 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 16/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 17 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 17/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 18 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 18/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 18/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 19 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 19/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 19/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 20 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 20/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 20/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 21 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 21/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 21/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 22 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 22/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 22/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 23 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 23/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 23/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 24 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 24/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 24/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 25 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 25/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 26 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 26/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 26/Signature 2 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 27 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 27/Signature 1 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 28 |
| The human microbiota is associated with cardiometabolic risk across the epidemiologic transition/Experiment 28/Signature 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 1 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 2 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 3 |
| The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial/Experiment 4 |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 1 |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 1/Signature 1 |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 1/Signature 2 |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 2 |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 2/Signature 1 |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 3 |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 3/Signature 1 |
| The lung microbiome in HIV-positive patients with active pulmonary tuberculosis/Experiment 3/Signature 2 |
| The nasal microbiome in asthma/Experiment 2 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 1 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 1/Signature 1 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 2 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 2/Signature 1 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 3 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 3/Signature 1 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 3/Signature 2 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 4 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 4/Signature 1 |
| The need for high-resolution gut microbiome characterization to design efficient strategies for sustainable aquaculture production/Experiment 4/Signature 2 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 1 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 2 |
| The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study/Experiment 3 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3 |
| The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 1 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 2 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 3 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 4 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 5 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 5/Signature 1 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 5/Signature 2 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 6 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 6/Signature 1 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 7 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 7/Signature 1 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 7/Signature 2 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 8 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 8/Signature 1 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 8/Signature 2 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 9 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 9/Signature 1 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 9/Signature 2 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 10 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 10/Signature 1 |
| The Parkinson's disease drug entacapone disrupts gut microbiome homoeostasis via iron sequestration/Experiment 10/Signature 2 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 1 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 1/Signature 1 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 1/Signature 2 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 2 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 2/Signature 1 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 3 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 3/Signature 1 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 4 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 4/Signature 1 |
| The penile microbiota of Black South African men: relationship with human papillomavirus and HIV infection/Experiment 4/Signature 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 1 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 2 |
| The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study/Experiment 3 |
| The vaginal microbiome is associated with endometrial cancer grade and histology |
| The vaginal microbiome is associated with endometrial cancer grade and histology/Experiment 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 1/Signature 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 1/Signature 2 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 2 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 2/Signature 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 2/Signature 2 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 3 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 3/Signature 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 3/Signature 2 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 4 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 4/Signature 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 4/Signature 2 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 5 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 5/Signature 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 5/Signature 2 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 6 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 6/Signature 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 6/Signature 2 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 7 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 7/Signature 1 |
| Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark/Experiment 7/Signature 2 |
| Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice |
| Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice/Experiment 1 |
| Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice/Experiment 1/Signature 1 |
| Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice/Experiment 1/Signature 2 |
| Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer |
| Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 1 |
| Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 1/Signature 1 |
| Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 1/Signature 2 |
| Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 2 |
| Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 2/Signature 1 |
| Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer/Experiment 2/Signature 2 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 1 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 2 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 3 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 4 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 5 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 6 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 7 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 8 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 9 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 10 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 11 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 12 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 13 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 14 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 15 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 16 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 17 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 18 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 19 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 20 |
| Tumor microbiome diversity influences papillary thyroid cancer invasion/Experiment 21 |
| Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents |
| Urogenital schistosomiasis is associated with signatures of microbiome dysbiosis in Nigerian adolescents/Experiment 1 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 1 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 1/Signature 1 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 1/Signature 2 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 2 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 2/Signature 1 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 2/Signature 2 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 3 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 3/Signature 1 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 3/Signature 2 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 4 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 4/Signature 1 |
| Visceral adiposity in postmenopausal women is associated with a pro-inflammatory gut microbiome and immunogenic metabolic endotoxemia/Experiment 4/Signature 2 |
| Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes |
| Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 1 |
| Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 1/Signature 1 |
| Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 1/Signature 2 |
| Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 2 |
| Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 2/Signature 1 |
| Whole metagenome sequencing of cecum microbiomes in Ethiopian indigenous chickens from two different altitudes reveals antibiotic resistance genes/Experiment 2/Signature 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 1 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 2 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 3 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 4 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 5 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 6 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 7 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 8 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 9 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 10 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 11 |
| Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques/Experiment 12 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 1/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 1/Signature 2 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 2 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 2/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 2/Signature 2 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 3 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 3/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 4 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 4/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 5 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 5/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 6 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 6/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 7 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 7/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 8 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 8/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 9 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 9/Signature 2 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 10 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 10/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 11 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 11/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 12 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 12/Signature 1 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 13 |
| Yoghurt consumption is associated with changes in the composition of the human gut microbiome and metabolome/Experiment 13/Signature 1 |
